Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1287 participants.

Also called NCT04755283

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose supportive care
Phase
Phase 2
Enrolled
  • 1,287 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04755283
  • EudraCT 2020-004507-13
Main results
  • Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation The New England journal of medicine, 2025-01-23 DOI, PubMed 39842011
Other papers using this trial's data
  • Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial Circulation, 2025-08-05 DOI, PubMed 40546068, PMC12668221 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial JAMA cardiology, 2026-03-01 DOI, PubMed 41637102, PMC12874071 Not in the PMC Open Access subset.
  • Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in the AZALEA-TIMI 71 study Blood, 2026-08-06 DOI, PubMed 42213637

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Hungary, Poland, South Korea, Taiwan (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04755283. Randomized; triple masking; primary purpose supportive care. Start 2021-02-02 (actual); primary completion 2024-02-15 (actual). Results posted on 2025-07-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
Acronym
AZALEA-TIMI 71
Condition
Atrial Fibrillation (AF)
Condition
Stroke
Intervention (Biological)
Abelacimab
Intervention (Drug)
Rivaroxaban
Lead sponsor
Anthos Therapeutics, Inc. (class: industry)
Collaborator
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct04755283
Content hash
c24778faeacf370f80a7fe12a1fcf857be93a94b7548347b8078142ce71f422e